Phase 1, Open Label, Sequential Cohort, Dose Escalation Study Of CP-751,871 In Combination With Sunitinib In Patients With Advanced Solid Tumors

Inclusion Criteria:

- Histologically or cytologically confirmed advanced solid tumors relapsed or
refractory to standard therapy or for whom no standard therapy exists.

- ECOG Performance Status of 0 or 1;

- Total IGF-1 level ≥100 ng/ml;

- ECOG Performance Status of 0 or 1

- Adequate bone marrow, renal, and hepatic function

Exclusion Criteria:

- Concurrent treatment with any antitumor agents with the exception of LHRH agnosits
for prostate cancer patients

- Treatment with any other investigational therapy within 4 weeks prior to study
treatment

- Major surgery within 4 weeks of study treatment

- Prior treatment that may increase the risk of cardiac complications

- Ongoing cardiac dysrhythmias of NCI CTCAE Grade 2 or greater

- Significant active cardiac disease, including hypertension that cannot be controlled
by medications

- Greater than three (3) prior lines of cytotoxic therapy;

- Active infection

- Prior IGF-IR targeted therapy;